Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000814170 | SCV000954571 | uncertain significance | Granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type 3 | 2022-10-25 | criteria provided, single submitter | clinical testing | This sequence change replaces methionine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 113 of the NCF4 protein (p.Met113Val). This variant is present in population databases (no rsID available, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with NCF4-related conditions. ClinVar contains an entry for this variant (Variation ID: 657545). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004028810 | SCV003529059 | uncertain significance | not specified | 2022-12-01 | criteria provided, single submitter | clinical testing | The c.337A>G (p.M113V) alteration is located in exon 4 (coding exon 4) of the NCF4 gene. This alteration results from a A to G substitution at nucleotide position 337, causing the methionine (M) at amino acid position 113 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |